NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Sepsis Therapeutics Industry
http://www.reportlinker.com/p0611042/Global-Sepsis-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_
This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. Analytics refer to sales of drugs used in the direct treatment of severe sepsis/septic shock. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 33 companies including many key and niche players such as Agennix AG, AstraZeneca Plc, Artisan Pharma, Atox Bio, Inc., CytoGenix, Inc., Chong Kun Dang Pharmaceutical Corporation, Daiichi-Sankyo Company, Ltd., Endacea, Inc., Eli Lilly and Company, Medinox, Inc., and NexBio, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
A Prelude 4
Snapshots 4
Table 1: Annual Incidence of Sepsis in the US and EU-27 5
Sepsis Treatment: An Untapped Market 5
Challenges Facing Sepsis Treatment 5
Lack of Awareness 5
Efforts to Enhance Awareness 6
Delayed Start of Treatment 6
Diagnostic Tools For Faster Treatment 7
Sepsis in Neonates: A Major Challenge 7
3. SEPSIS - AN INTRODUCTION 8
Sepsis - A Leading Killer 8
Risk Profile 8
Most Vulnerable Group: New Born and Elderly 8
A Growing Threat in Hospital Environment 9
Types of Sepsis 9
SIRS 9
Uncomplicated Sepsis 10
Severe Sepsis 10
Septic Shock 10
Septicemia 10
Bacteremia 10
Mortality Rates 11
Table 2: 28-Day Mortality Rate: Progression from Infection to
Septic Shock 11
Symptoms to Identify Sepsis Patients 11
General Symptoms in Sepsis Patients 11
Symptoms Specific to Source of Infection 12
Biological Changes in Sepsis Patients 12
Organ Dysfunction Symptoms in Acute Cases 12
Common Sources of Sepsis 13
Table 3: Primary Site of Infection Affected by Sepsis
(includes corresponding Graph/Chart) 13
Stages of Sepsis' Progression 13
Treatment of Sepsis 14
General Approaches for Treatment of Severe Sepsis and Septic
Shock 14
First Line of Treatment 15
Identifying Infection Source 15
Overview of Traditional Treatment Approaches 15
Corticosteroids 16
Immunoglobulins 16
Anticoagulants 17
Neonatal Sepsis 17
4. DRUGS FOR SEPSIS TREATMENT: AN OVERVIEW 18
Xigris - The Only Approved Treatment for Sepsis 18
Declining Sales: A Cause of Concern for Xigris Brand 18
PROWESS Study 19
Artisan Pharma's ART 123 19
AstraZeneca's CytoFab™ 19
Agennix's Talactoferrin 20
Chong Kun Dang Pharmaceutical's CKD-712 20
Eisai's Eritoran 20
Takeda's TAK-242 20
Current Development Status of Select Sepsis Drugs 21
Primary Completion Dates of Select Sepsis Therapeutics 22
5. STRATEGIC CORPORATE DEVELOPMENTS 23
Eisai's Eritoran Fails Phase III Trial 23
Rhode Island Hospital Identifies New Protein 23
Agennix Offers Data from Talactoferrin Phase II Trial 23
Nycomed Acquires Majority Interest in Guangdong Techpool Bio-
Pharma 23
Tianjin Chase Collaborates with Chongging Southwest Hospital
for Developing Sepsis Drug 24
Artisan Pharma Announces Phase IIb Study of ART-123 24
AstraZeneca Commences Phase IIb Trials for CytoFab™ 25
Medinox Collaborates with Orient Europharma for NOX-100 25
GPC Biotech Signs Business Combination Agreement with Agennix 25
Fast-Track Drugs & Biologics and Atox Bio Enter into
Collaboration 26
Sirius Genomics Enters into Agreement with Assistance
Publique-Hopitaux de Paris 26
Takeda Discontinues Compound Development for Severe Sepsis 27
BTG Acquires Protherics 27
Galapagos and UCL Sign Agreement 27
Artisan Pharma Receives Approval for ART-123 in Japan 27
6. FOCUS ON SELECT PLAYERS 28
Agennix AG (Germany) 28
AstraZeneca Plc (UK) 28
Artisan Pharma (US) 29
Atox Bio, Inc. (US) 29
CytoGenix, Inc. (US) 30
Chong Kun Dang Pharmaceutical Corporation (Korea) 30
Daiichi-Sankyo Company, Ltd. (Japan) 30
Endacea, Inc. (US) 31
Eli Lilly and Company (US) 31
Medinox, Inc. 32
NexBio, Inc. (US) 32
7. GLOBAL MARKET PERSPECTIVE 33
Table 4: World Recent Past, Current and Future Analysis for
Sepsis Drugs by Geographic Region - US and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 33
Table 5: World Historic Review for Sepsis Drugs by Geographic
Region - US and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) 34
Table 6: World 15-Year Perspective for Sepsis Drugs by
Geographic Region - Percentage Breakdown of Value Sales for US
and Rest of World Markets for Years 2003, 2010, and 2017
(includes corresponding Graph/Chart) 34
8. THE UNITED STATES 35
A.Market Analysis 35
Outlook 35
Snapshots 35
Rising Incidence of Healthcare Infections 35
Sepsis: A Leading Cause of Mortality in the US 36
Table 7: Incidence and Mortality Rate of Select Diseases in
the US 36
Table 8: Number of Deaths Per Annum of Select Diseases in
the US 36
An Economic Burden 36
Risk of Sepsis in Neonates 37
Reimbursement Scenario 37
B.Market Analytics 38
Table 9: US Recent Past, Current and Future Analysis for
Sepsis Drugs Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 38
Table 10: US Historic Review for Sepsis Drugs Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 38
9. REST OF WORLD 39
A.Market Analysis 39
Outlook 39
Canada 39
Table 11: Mortality Rate (%) of Select Conditions in Canada 39
Europe 39
United Kingdom 39
Drotrecogin Alfa (Activated): Recommended for High-Risk
Sepsis Patients 40
The Netherlands 40
Poland 40
B.Market Analytics 41
Table 12: Rest of World Recent Past, Current and Future
Analysis for Sepsis Drugs Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 41
Table 13: Rest of World Historic Review for Sepsis Drugs
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 41
COMPETITIVE LANDSCAPE
Total Companies Profiled: 33 (including Divisions/Subsidiaries - 35)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 17
Canada 1
Japan 2
Europe 9
France 1
Germany 2
The United Kingdom 3
Rest of Europe 3
Asia-Pacific (Excluding Japan) 4
Middle East 2
------------------------------------------
To order this report:
Drug and Medication Industry: Global Sepsis Therapeutics Industry
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article